The persisting challenge of selective and specific proteasome inhibition

Groll, Michael, Huber, Robert and Moroder, Luis 2009. The persisting challenge of selective and specific proteasome inhibition. Journal of Peptide Science 15 (2) , pp. 58-66. 10.1002/psc.1107

Full text not available from this repository.

Abstract

Since the discovery of the proteasome and its structure elucidation intensive research programs in academic institutions and pharmaceutical industries led to identification of a wide spectrum of synthetic and natural small proteasomal inhibitors. Activity studies with these small molecules helped to deeply understand the complex biochemical organization and functioning of the proteasome. The new structural and biochemical insights placed the proteasome as an important anti-cancer drug target, as revealed by the dipeptide boronate proteasome inhibitor, bortezomib, which is currently used for treatment of multiple myeloma. Serious side effects and partial cell resistance against bortezomib demand creation and discovery of new improved generations of more specific and potent proteasomal inhibitors.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences
Subjects:	Q Science > Q Science (General) Q Science > QD Chemistry
Uncontrolled Keywords:	proteasome; inhibitors; synthetic and natural products; crystallographic analysis; polyvalency
Additional Information:	Article first published online: 24 DEC 2008
Publisher:	Wiley
ISSN:	1075-2617
Related URLs:	http://onlinelibrary.wiley.com/doi/10.10... http://www.ncbi.nlm.nih.gov/pubmed/19109... http://www.eurpepsoc.com/details/news/19... http://www.mendeley.com/research/the-per...
Last Modified:	24 Jun 2017 08:43
URI:	https://orca.cardiff.ac.uk/id/eprint/18218

Citation Data

Cited 60 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item